Radionuclide-based molecular imaging allows CAR-T cellular visualization and therapeutic monitoring

Shao, Fuqiang; Long, Yu; Ji, Hao; Jiang, Dawei; Lei, Ping; Lan, Xiaoli

doi:10.7150/thno.56989



Nanotheranostics 2024; 8(3): 380-400. [Abstract] [Full text] [PDF]

Nanotheranostics 2024; 8(3): 344-379. [Abstract] [Full text] [PDF] [PubMed] [PMC]

Nanotheranostics

International Journal of Biological Sciences

International Journal of Medical Sciences

Journal of Cancer

Global reach, higher impact

Full Text | PDF

Theranostics 2021; 11(14):6800-6817. doi:10.7150/thno.56989 This issue Cite

Research Paper

Radionuclide-based molecular imaging allows CAR-T cellular visualization and therapeutic monitoring

Fuqiang Shao^1,2,3,4, Yu Long^1,2, Hao Ji^1,2, Dawei Jiang^1,2, Ping Lei⁵, Xiaoli Lan^1,2✉

1. Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
2. Hubei Key Laboratory of Molecular Imaging, Wuhan 430022, China.
3. Department of nuclear medicine, Zigong First People's Hospital, Zigong 643000, China.
4. Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Luzhou 646000, China.
5. Department of Immunology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.

Citation:

Shao F, Long Y, Ji H, Jiang D, Lei P, Lan X. Radionuclide-based molecular imaging allows CAR-T cellular visualization and therapeutic monitoring. Theranostics 2021; 11(14):6800-6817. doi:10.7150/thno.56989. https://www.thno.org/v11p6800.htm

Other styles

Abstract

Chimeric antigen receptor T cell (CAR-T) therapy is a new and effective form of adoptive cell therapy that is rapidly entering the mainstream for the treatment of CD19-positive hematological cancers because of its impressive effect and durable responses. Huge challenges remain in achieving similar success in patients with solid tumors. The current methods of monitoring CAR-T, including morphological imaging (CT and MRI), blood tests, and biopsy, have limitations to assess whether CAR-T cells are homing to tumor sites and infiltrating into tumor bed, or to assess the survival, proliferation, and persistence of CAR-T cells in solid tumors associated with an immunosuppressive microenvironment. Radionuclide-based molecular imaging affords improved CAR-T cellular visualization and therapeutic monitoring through either a direct cellular radiolabeling approach or a reporter gene imaging strategy, and endogenous cell imaging is beneficial to reflect functional information and immune status of T cells. Focusing on the dynamic monitoring and precise assessment of CAR-T therapy, this review summarizes the current applications of radionuclide-based noninvasive imaging in CAR-T cells visualization and monitoring and presents current challenges and strategic choices.

Keywords: chimeric antigen receptor T cell, molecular imaging, side effects, therapeutic monitoring, direct labeling, reporter gene, endogenous cell

Citation styles

APA

Shao, F., Long, Y., Ji, H., Jiang, D., Lei, P., Lan, X. (2021). Radionuclide-based molecular imaging allows CAR-T cellular visualization and therapeutic monitoring. Theranostics, 11(14), 6800-6817. https://doi.org/10.7150/thno.56989.

ACS

Shao, F.; Long, Y.; Ji, H.; Jiang, D.; Lei, P.; Lan, X. Radionuclide-based molecular imaging allows CAR-T cellular visualization and therapeutic monitoring. Theranostics 2021, 11 (14), 6800-6817. DOI: 10.7150/thno.56989.

NLM

CSE

Shao F, Long Y, Ji H, Jiang D, Lei P, Lan X. 2021. Radionuclide-based molecular imaging allows CAR-T cellular visualization and therapeutic monitoring. Theranostics. 11(14):6800-6817.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.